Literature DB >> 18727647

The importance of placebo in headache research.

H-C Diener1, C F Schorn, U Bingel, D W Dodick.   

Abstract

The best way to appreciate the efficacy of drug and behavioural therapy in the acute and prophylactic treatment of headache is to perform placebo-controlled randomized trials. In order to plan and conduct these studies in the most appropriate way, it is desirable to know which factors influence the placebo response. This paper reviews factors which influence the placebo response in clinical trials, such as expectation, blinding, route of application of drugs and age, gender and geographical distribution. Response rates of placebo in the treatment of acute headache episodes are higher than in headache prophylaxis. Invasive procedures such as injections have a higher placebo response compared with oral drugs. Variables known to influence the placebo response have to be taken into consideration to calculate properly the power of planned randomized trials.

Entities:  

Mesh:

Year:  2008        PMID: 18727647     DOI: 10.1111/j.1468-2982.2008.01660.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  35 in total

1.  OnabotulinumtoxinA: preventive treatment for chronic migraine.

Authors:  Shih-Pin Chen; Jong-Ling Fuh; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2011-02

Review 2.  [The value of "migraine surgery". Overview of the pathophysiological concept and current evidence].

Authors:  C Gaul; D Holle; P S Sandor; S Evers; G Broessner; A Straube; H-C Diener
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

Review 3.  [Migraine myths].

Authors:  H Wilhelm
Journal:  Ophthalmologe       Date:  2012-03       Impact factor: 1.059

4.  Occipital nerve stimulation for chronic migraine.

Authors:  William B Young
Journal:  Curr Pain Headache Rep       Date:  2014-02

5.  Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.

Authors:  Vladimir Skljarevski; Tina M Oakes; Qi Zhang; Margaret B Ferguson; James Martinez; Angelo Camporeale; Kirk W Johnson; Qiuling Shan; Jeffrey Carter; Aaron Schacht; Peter J Goadsby; David W Dodick
Journal:  JAMA Neurol       Date:  2018-02-01       Impact factor: 18.302

6.  Cluster headache and oxygen: is it possible to predict which patients will be relieved? A retrospective cross-sectional correlation study.

Authors:  A P M Backx; D Y P Haane; L De Ceuster; P J Koehler
Journal:  J Neurol       Date:  2010-04-27       Impact factor: 4.849

Review 7.  Pain Modulation: From Conditioned Pain Modulation to Placebo and Nocebo Effects in Experimental and Clinical Pain.

Authors:  Janie Damien; Luana Colloca; Carmen-Édith Bellei-Rodriguez; Serge Marchand
Journal:  Int Rev Neurobiol       Date:  2018-08-14       Impact factor: 3.230

Review 8.  What Constitutes an "Adequate" Trial in Migraine Prevention?

Authors:  Jonathan H Smith; Todd J Schwedt
Journal:  Curr Pain Headache Rep       Date:  2015-11

9.  Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting.

Authors:  Gereon Nelles; Lukas Schmitt; Thomas Humbert; Veit Becker; Petra Sandow; Karin Bornhoevd; Dirk Fritzsche; Barbara Schäuble
Journal:  J Headache Pain       Date:  2009-11-06       Impact factor: 7.277

10.  Brief intervention by general practitioners for medication-overuse headache, follow-up after 6 months: a pragmatic cluster-randomised controlled trial.

Authors:  Espen Saxhaug Kristoffersen; Jørund Straand; Kjersti Grøtta Vetvik; Jūratė Šaltytė Benth; Michael Bjørn Russell; Christofer Lundqvist
Journal:  J Neurol       Date:  2015-12-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.